Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies
A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental...
Gespeichert in:
Veröffentlicht in: | Digestive diseases and sciences 1997-05, Vol.42 (5), p.1029-1037 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1037 |
---|---|
container_issue | 5 |
container_start_page | 1029 |
container_title | Digestive diseases and sciences |
container_volume | 42 |
creator | SIKIRIC, P MIKUS, D ZORICIC, I PERIC, J KONJEVODA, P PEROVIC, D JURINA, L HANZEVACKI, M SEPAROVIC, J GJURASIN, M JADRIJEVIC, S JELOVAC, N SEIWERTH, S MIKLIC, P BULJAT, G MAROVIC, A GRABAREVIC, Z RUCMAN, R PETEK, M JAGIC, V TURKOVIC, B ROTKVIC, I MISE, S |
description | A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed. |
doi_str_mv | 10.1023/A:1018893220943 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_214338137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>404185571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-35a220a4a29c7a852df592fe9e5c188c24b7a3cabbb50f61af51ed6beaa312493</originalsourceid><addsrcrecordid>eNo9kE9vFDEMxSMEKtvCmRNShDh2IX8mM5PelhWllSq1BzivPImDUs1MhiRbaful-Ip4xcLJ9vNPz9Zj7J0Un6RQ-vPmSgrZ91YrJWyjX7CVNJ1eK9P2L9lKyJZ6KdvX7LyURyGE7WR7xs6sbKww_Yr9fsC5gkcHCy41euRfHracPC65ixOSEme85Bnm-K8fcpqSy5Hw4wiz51BzWmjiGAK6yuPM3aFUhOkojlhimstRranCOB74Tyg1E0lW8Rk9-dfCr_iGT8njyEPKZFDTklMlKj4hL3XvI5Y37FWAseDbU71gP66_ft_erO_uv91uN3drp0Vf19oABQINKOs66I3ywVgV0KJxFJdTzdCBdjAMgxGhlRCMRN8OCKClaqy-YB_--tILv_ZY6u4x7fNMJ3dKNlr3UncEvT9B-2FCv1tynCAfdqd0af_xtIfiYAyUoovlP6batmuU0n8AVr2MHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214338137</pqid></control><display><type>article</type><title>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>SIKIRIC, P ; MIKUS, D ; ZORICIC, I ; PERIC, J ; KONJEVODA, P ; PEROVIC, D ; JURINA, L ; HANZEVACKI, M ; SEPAROVIC, J ; GJURASIN, M ; JADRIJEVIC, S ; JELOVAC, N ; SEIWERTH, S ; MIKLIC, P ; BULJAT, G ; MAROVIC, A ; GRABAREVIC, Z ; RUCMAN, R ; PETEK, M ; JAGIC, V ; TURKOVIC, B ; ROTKVIC, I ; MISE, S</creator><creatorcontrib>SIKIRIC, P ; MIKUS, D ; ZORICIC, I ; PERIC, J ; KONJEVODA, P ; PEROVIC, D ; JURINA, L ; HANZEVACKI, M ; SEPAROVIC, J ; GJURASIN, M ; JADRIJEVIC, S ; JELOVAC, N ; SEIWERTH, S ; MIKLIC, P ; BULJAT, G ; MAROVIC, A ; GRABAREVIC, Z ; RUCMAN, R ; PETEK, M ; JAGIC, V ; TURKOVIC, B ; ROTKVIC, I ; MISE, S</creatorcontrib><description>A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1023/A:1018893220943</identifier><identifier>PMID: 9149058</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Animals ; Anti-Ulcer Agents - pharmacology ; Atropine - pharmacology ; Biological and medical sciences ; Bromocriptine - pharmacology ; Cimetidine - pharmacology ; Cysteamine - toxicity ; Digestive system ; Duodenal Ulcer - chemically induced ; Duodenal Ulcer - prevention & control ; Female ; Gastrectomy ; Medical sciences ; Omeprazole - pharmacology ; Peptide Fragments - pharmacology ; Pharmacology. Drug treatments ; Proteins - pharmacology ; Ranitidine - pharmacology ; Rats ; Rats, Wistar</subject><ispartof>Digestive diseases and sciences, 1997-05, Vol.42 (5), p.1029-1037</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers May 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c308t-35a220a4a29c7a852df592fe9e5c188c24b7a3cabbb50f61af51ed6beaa312493</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2667422$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9149058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SIKIRIC, P</creatorcontrib><creatorcontrib>MIKUS, D</creatorcontrib><creatorcontrib>ZORICIC, I</creatorcontrib><creatorcontrib>PERIC, J</creatorcontrib><creatorcontrib>KONJEVODA, P</creatorcontrib><creatorcontrib>PEROVIC, D</creatorcontrib><creatorcontrib>JURINA, L</creatorcontrib><creatorcontrib>HANZEVACKI, M</creatorcontrib><creatorcontrib>SEPAROVIC, J</creatorcontrib><creatorcontrib>GJURASIN, M</creatorcontrib><creatorcontrib>JADRIJEVIC, S</creatorcontrib><creatorcontrib>JELOVAC, N</creatorcontrib><creatorcontrib>SEIWERTH, S</creatorcontrib><creatorcontrib>MIKLIC, P</creatorcontrib><creatorcontrib>BULJAT, G</creatorcontrib><creatorcontrib>MAROVIC, A</creatorcontrib><creatorcontrib>GRABAREVIC, Z</creatorcontrib><creatorcontrib>RUCMAN, R</creatorcontrib><creatorcontrib>PETEK, M</creatorcontrib><creatorcontrib>JAGIC, V</creatorcontrib><creatorcontrib>TURKOVIC, B</creatorcontrib><creatorcontrib>ROTKVIC, I</creatorcontrib><creatorcontrib>MISE, S</creatorcontrib><title>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.</description><subject>Animals</subject><subject>Anti-Ulcer Agents - pharmacology</subject><subject>Atropine - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bromocriptine - pharmacology</subject><subject>Cimetidine - pharmacology</subject><subject>Cysteamine - toxicity</subject><subject>Digestive system</subject><subject>Duodenal Ulcer - chemically induced</subject><subject>Duodenal Ulcer - prevention & control</subject><subject>Female</subject><subject>Gastrectomy</subject><subject>Medical sciences</subject><subject>Omeprazole - pharmacology</subject><subject>Peptide Fragments - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Proteins - pharmacology</subject><subject>Ranitidine - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNo9kE9vFDEMxSMEKtvCmRNShDh2IX8mM5PelhWllSq1BzivPImDUs1MhiRbaful-Ip4xcLJ9vNPz9Zj7J0Un6RQ-vPmSgrZ91YrJWyjX7CVNJ1eK9P2L9lKyJZ6KdvX7LyURyGE7WR7xs6sbKww_Yr9fsC5gkcHCy41euRfHracPC65ixOSEme85Bnm-K8fcpqSy5Hw4wiz51BzWmjiGAK6yuPM3aFUhOkojlhimstRranCOB74Tyg1E0lW8Rk9-dfCr_iGT8njyEPKZFDTklMlKj4hL3XvI5Y37FWAseDbU71gP66_ft_erO_uv91uN3drp0Vf19oABQINKOs66I3ywVgV0KJxFJdTzdCBdjAMgxGhlRCMRN8OCKClaqy-YB_--tILv_ZY6u4x7fNMJ3dKNlr3UncEvT9B-2FCv1tynCAfdqd0af_xtIfiYAyUoovlP6batmuU0n8AVr2MHg</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>SIKIRIC, P</creator><creator>MIKUS, D</creator><creator>ZORICIC, I</creator><creator>PERIC, J</creator><creator>KONJEVODA, P</creator><creator>PEROVIC, D</creator><creator>JURINA, L</creator><creator>HANZEVACKI, M</creator><creator>SEPAROVIC, J</creator><creator>GJURASIN, M</creator><creator>JADRIJEVIC, S</creator><creator>JELOVAC, N</creator><creator>SEIWERTH, S</creator><creator>MIKLIC, P</creator><creator>BULJAT, G</creator><creator>MAROVIC, A</creator><creator>GRABAREVIC, Z</creator><creator>RUCMAN, R</creator><creator>PETEK, M</creator><creator>JAGIC, V</creator><creator>TURKOVIC, B</creator><creator>ROTKVIC, I</creator><creator>MISE, S</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>19970501</creationdate><title>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</title><author>SIKIRIC, P ; MIKUS, D ; ZORICIC, I ; PERIC, J ; KONJEVODA, P ; PEROVIC, D ; JURINA, L ; HANZEVACKI, M ; SEPAROVIC, J ; GJURASIN, M ; JADRIJEVIC, S ; JELOVAC, N ; SEIWERTH, S ; MIKLIC, P ; BULJAT, G ; MAROVIC, A ; GRABAREVIC, Z ; RUCMAN, R ; PETEK, M ; JAGIC, V ; TURKOVIC, B ; ROTKVIC, I ; MISE, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-35a220a4a29c7a852df592fe9e5c188c24b7a3cabbb50f61af51ed6beaa312493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Anti-Ulcer Agents - pharmacology</topic><topic>Atropine - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bromocriptine - pharmacology</topic><topic>Cimetidine - pharmacology</topic><topic>Cysteamine - toxicity</topic><topic>Digestive system</topic><topic>Duodenal Ulcer - chemically induced</topic><topic>Duodenal Ulcer - prevention & control</topic><topic>Female</topic><topic>Gastrectomy</topic><topic>Medical sciences</topic><topic>Omeprazole - pharmacology</topic><topic>Peptide Fragments - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Proteins - pharmacology</topic><topic>Ranitidine - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SIKIRIC, P</creatorcontrib><creatorcontrib>MIKUS, D</creatorcontrib><creatorcontrib>ZORICIC, I</creatorcontrib><creatorcontrib>PERIC, J</creatorcontrib><creatorcontrib>KONJEVODA, P</creatorcontrib><creatorcontrib>PEROVIC, D</creatorcontrib><creatorcontrib>JURINA, L</creatorcontrib><creatorcontrib>HANZEVACKI, M</creatorcontrib><creatorcontrib>SEPAROVIC, J</creatorcontrib><creatorcontrib>GJURASIN, M</creatorcontrib><creatorcontrib>JADRIJEVIC, S</creatorcontrib><creatorcontrib>JELOVAC, N</creatorcontrib><creatorcontrib>SEIWERTH, S</creatorcontrib><creatorcontrib>MIKLIC, P</creatorcontrib><creatorcontrib>BULJAT, G</creatorcontrib><creatorcontrib>MAROVIC, A</creatorcontrib><creatorcontrib>GRABAREVIC, Z</creatorcontrib><creatorcontrib>RUCMAN, R</creatorcontrib><creatorcontrib>PETEK, M</creatorcontrib><creatorcontrib>JAGIC, V</creatorcontrib><creatorcontrib>TURKOVIC, B</creatorcontrib><creatorcontrib>ROTKVIC, I</creatorcontrib><creatorcontrib>MISE, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SIKIRIC, P</au><au>MIKUS, D</au><au>ZORICIC, I</au><au>PERIC, J</au><au>KONJEVODA, P</au><au>PEROVIC, D</au><au>JURINA, L</au><au>HANZEVACKI, M</au><au>SEPAROVIC, J</au><au>GJURASIN, M</au><au>JADRIJEVIC, S</au><au>JELOVAC, N</au><au>SEIWERTH, S</au><au>MIKLIC, P</au><au>BULJAT, G</au><au>MAROVIC, A</au><au>GRABAREVIC, Z</au><au>RUCMAN, R</au><au>PETEK, M</au><au>JAGIC, V</au><au>TURKOVIC, B</au><au>ROTKVIC, I</au><au>MISE, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>42</volume><issue>5</issue><spage>1029</spage><epage>1037</epage><pages>1029-1037</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged. BPC 157 was compared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings--equal damaging effect of cysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach--seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high "cytoprotective capacity," apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>9149058</pmid><doi>10.1023/A:1018893220943</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-2116 |
ispartof | Digestive diseases and sciences, 1997-05, Vol.42 (5), p.1029-1037 |
issn | 0163-2116 1573-2568 |
language | eng |
recordid | cdi_proquest_journals_214338137 |
source | MEDLINE; SpringerLink Journals |
subjects | Animals Anti-Ulcer Agents - pharmacology Atropine - pharmacology Biological and medical sciences Bromocriptine - pharmacology Cimetidine - pharmacology Cysteamine - toxicity Digestive system Duodenal Ulcer - chemically induced Duodenal Ulcer - prevention & control Female Gastrectomy Medical sciences Omeprazole - pharmacology Peptide Fragments - pharmacology Pharmacology. Drug treatments Proteins - pharmacology Ranitidine - pharmacology Rats Rats, Wistar |
title | Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats : A model for cytoprotective studies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A29%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentadecapeptide%20BPC%20157,%20cimetidine,%20ranitidine,%20bromocriptine,%20and%20atropine%20effect%20in%20cysteamine%20lesions%20in%20totally%20gastrectromized%20rats%20:%20A%20model%20for%20cytoprotective%20studies&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=SIKIRIC,%20P&rft.date=1997-05-01&rft.volume=42&rft.issue=5&rft.spage=1029&rft.epage=1037&rft.pages=1029-1037&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1023/A:1018893220943&rft_dat=%3Cproquest_pubme%3E404185571%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214338137&rft_id=info:pmid/9149058&rfr_iscdi=true |